Business Context and Reporting Period
Company: American Healthcare REIT, Inc. (AHR)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2025
Event: Entry into a Material Definitive Agreement (ATM Equity Offering Sales Agreement).
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a new capital raising facility:
- Aggregate Gross Sales Price: Up to $1 billion in Common Stock.
- Commission Rate: Up to 2.0% of the gross sales price for shares sold through Agents.
- Forward Sale Commission: Up to 2.0% of the gross sales price per share for forward sale agreements.
- Debt and Liquidity: The filing does not provide current debt balances or liquidity figures, but notes proceeds may be used to repay indebtedness.
Material Changes Versus Prior Period
Termination of Prior Program: Upon entering the new Sales Agreement, the Company terminated its prior at-the-market offering program dated November 18, 2024. No shares remained unsold under the prior agreement at the time of termination.
Expansion of Capacity: The new agreement establishes a fresh capacity to raise up to $1 billion, replacing the exhausted prior facility.
Guidance, Outlook, and Management Commentary
Use of Proceeds: Net proceeds will be contributed to the Operating Partnership for general corporate purposes, including:
- Repaying or repurchasing indebtedness (including lines of credit).
- Working capital.
- Capital expenditures.
- Potential future investments.
Sale Mechanics: Sales will be determined based on market conditions, trading price, and capital needs. The Company may sell shares via "at-the-market" offerings, negotiated transactions, or forward sale agreements. Forward sale agreements allow the Company to lock in a forward price subject to daily interest rate adjustments and dividend reductions.
Risks and Contingencies: The filing notes that the Company will not receive proceeds from shares borrowed by Forward Purchasers and sold to hedge exposure. The forward price is subject to daily reduction if the specified daily rate is less than the applicable spread.
Important Facts for Investor Verification
- Verify the current trading price of AHR common stock to assess potential dilution from the $1 billion offering.
- Confirm the specific terms of any forward sale agreements entered into, particularly the interest rate spread and dividend adjustment mechanisms.
- Monitor future filings for the actual volume of shares sold and the net proceeds received after commissions.
- Review the Company's latest 10-Q or 10-K for current debt levels to understand the urgency of the "repaying indebtedness" use of proceeds.